Does Anthem (Elevance Health) Cover Belsomra (Suvorexant)?

Belsomra (suvorexant) is a brand-name, prescription-only insomnia medication and a Schedule IV controlled substance. It belongs to a drug class called dual orexin receptor antagonists (DORAs), which block the brain's wake-promoting orexin signal rather than broadly sedating the central nervous system the way older benzodiazepine-type hypnotics do. It is not the same drug as lemborexant (Dayvigo), a newer DORA, or low-dose doxepin (Silenor), an older tricyclic antidepressant repurposed at low doses for sleep maintenance.

The short answer: Anthem (Elevance Health) commercial plans generally do cover Belsomra, but coverage is not automatic. Brand-name hypnotics like this one are typically placed above generic sleep medications in an insurer's formulary hierarchy, which usually means prior authorization and a documented trial of a generic option first. The specific tier, copay amount, and prior-authorization wording are set at the plan level and change by state, plan type, and benefit year, so no single article can state your exact cost or approval odds with certainty.

The core answer, stated plainly

Belsomra is FDA-approved for insomnia involving difficulty with sleep onset, sleep maintenance, or both, under a label first approved in August 2014. Most commercial insurers, including Anthem/Elevance Health plans, require prior authorization and evidence that a generic sleep medication (commonly zolpidem, trazodone, or eszopiclone) was tried and failed before they approve a brand-name orexin antagonist like Belsomra, because these agents typically sit above generics in step-therapy hierarchies. The exact formulary tier, copay, and prior-authorization criteria differ by state, plan design, and benefit year, so confirming your own coverage requires checking your plan's current formulary document, your Explanation of Benefits, or Anthem member services directly, not a general guide like this one.

What "requires prior authorization" actually means for you

Insurers use prior authorization (PA) to confirm that a brand-name drug is clinically necessary before paying for it. For a drug like Belsomra, a typical PA request from a prescriber would need to document:

• A diagnosed insomnia disorder
• A trial of at least one covered generic hypnotic, including the dose and how long it was used
• Why that generic failed or caused unacceptable side effects
• Any contraindication to generic alternatives, if relevant

This general pattern is common across commercial insurers for non-preferred brand drugs. Whether Anthem's specific criteria match this exactly, and what counts as an "adequate trial" in days or dosing, is set in Anthem's own clinical policy documents, which are updated periodically and are not fully reproduced in public sources reviewed for this article. If your prescriber is submitting a PA request, ask them to pull Anthem's current published policy for suvorexant, or call the number on your insurance card and request the specific clinical criteria in writing.

What Belsomra is likely to cost you

Brand-name drugs without a generic equivalent are usually placed on a non-preferred brand tier, which carries a higher copay or coinsurance than generic tiers. As of this review, no generic version of suvorexant has been approved in the United States; you can confirm current generic status through the FDA's Orange Book search tool, since patent and exclusivity status can change.

Manufacturers of brand hypnotics have historically offered savings card programs for commercially insured patients, and cash-pay discount programs (through pharmacy discount cards or membership pharmacies) can sometimes undercut an insurance copay for a non-preferred brand tier. The exact discount amounts, eligibility rules, and annual caps for any current savings program change over time and are set by the manufacturer, not by Anthem, so check the manufacturer's current program terms directly rather than relying on a fixed number here. These programs typically cannot be combined with government insurance such as Medicare, Medicaid, or TRICARE.

What the FDA label establishes about the drug itself

The FDA label for suvorexant specifies a starting dose of 10 mg taken within 30 minutes of bedtime, with at least 7 hours of intended sleep time remaining, and allows an increase to 20 mg if the lower dose is tolerated but not effective enough. The label lists narcolepsy as a contraindication, since blocking orexin receptors in a patient who already has low orexin activity can worsen symptoms. It also flags an interaction with strong CYP3A4 inhibitors, which raise suvorexant blood levels and increase sedation risk. This is FDA-approved dosing information for prescriber reference, not individualized dosing guidance, and any dose changes should be made by the prescribing clinician based on the individual's response and other medications.

Clinical trial data submitted for FDA approval found that suvorexant improved subjective measures of falling asleep and staying asleep compared to placebo in adults with insomnia. The precise magnitude of that benefit, and how it compares numerically to generic hypnotics or to low-dose doxepin, is described in the peer-reviewed trial literature and guideline documents; because the specific study identifiers available for this rewrite could not be verified against the primary literature, exact numbers are intentionally omitted here. If you want the precise effect sizes, ask your prescriber for the specific trial citation or look up the FDA label's clinical studies section directly.

What guideline bodies say, in general terms

Sleep medicine guideline groups, including the American Academy of Sleep Medicine, have published pharmacologic treatment guidance for chronic insomnia that generally favors cognitive behavioral therapy for insomnia (CBT-I) as a first-line approach, with medication considered for patients who cannot access or do not respond to CBT-I. Where drug therapy is used, these guidelines have historically treated suvorexant and low-dose doxepin as options of broadly similar recommendation strength for sleep maintenance problems, without ranking one brand drug clearly above the class of generic options. If a specific guideline recommendation matters to your care or your appeal, ask your prescriber to cite the current version of that guideline directly, since these documents are periodically updated.

If Anthem denies the prior authorization

Federal law under the Affordable Care Act gives commercially insured members the right to internal appeal followed by external review by an independent review organization (IRO) if internal appeals are exhausted. In general:

• A first-level internal appeal is usually available within a defined window after a denial (commonly around 180 days, but confirm the deadline stated on your specific denial letter).
• If that fails, a second internal review is typically available.
• After internal appeals are exhausted, you can request an external IRO review through your state insurance department.

Research organizations including the Kaiser Family Foundation have studied how often external review overturns insurer denials, but overturn rates vary by state, drug class, and time period, and a single number should not be treated as a prediction for your specific appeal. If you are appealing, the most useful thing you can do is match your response directly to the reason stated on the denial letter (for example, "step therapy not completed" needs pharmacy claims proof that a generic was tried, while "not medically necessary" needs clinical documentation and guideline support).

Alternatives worth discussing with your prescriber

If Belsomra is denied, delayed, or too expensive under your plan, reasonable alternatives to discuss include:

• Zolpidem, eszopiclone, or trazodone, generic, usually lower-tier, often the required first step
• Low-dose doxepin (Silenor and generics), available generically, useful mainly for sleep maintenance rather than sleep onset difficulty
• Lemborexant (Dayvigo), another orexin antagonist, generally facing similar brand-tier and step-therapy hurdles as Belsomra rather than being an easier path
• CBT-I, a non-drug, guideline-favored first-line approach, sometimes covered as a separate behavioral health benefit

None of these is a substitute for individualized prescribing. A clinician needs to weigh your specific sleep complaint (trouble falling asleep versus trouble staying asleep), other medications, liver function, and substance use history before choosing among them.

What is established, what is plausible, and what is not established

Established: Suvorexant is FDA-approved for insomnia, is a Schedule IV controlled substance, has label-specified dosing and contraindications, and commercial insurers commonly require prior authorization and step therapy for non-preferred brand hypnotics.

Plausible but not confirmed by the sources reviewed here: The exact dollar copay range, exact PA turnaround times, and exact appeal overturn rates cited in earlier versions of pages like this one are the kind of numbers insurers do publish, but they were not verifiable against a primary Anthem or regulator source at the time of this review and should not be treated as current facts.

Not established: Any claim that a specific documentation strategy guarantees PA approval, or that a specific savings card amount currently applies. Insurance policy and manufacturer program terms change and require direct verification.

Verification framework: what to check before you assume coverage or denial

Use this sequence instead of relying on a general guide, since your plan year, state, and specific Anthem product (commercial, Medicare Advantage, or Medicaid managed care) all change the answer.

Frequently asked questions

Does Anthem cover Belsomra for anything other than insomnia? No. Belsomra is FDA-approved only for insomnia involving difficulty with sleep onset, sleep maintenance, or both. There is no approved indication for weight loss or other uses, and an insurer would not be expected to approve coverage for an unapproved use without strong clinical justification, which is uncommon for this drug.

Do I need to try a generic sleep medication before Anthem will approve Belsomra? Most commercial insurers, likely including Anthem, require this kind of step therapy for non-preferred brand hypnotics. The exact list of qualifying generics and the required trial length are set by Anthem's current clinical policy, which your prescriber's office can request directly.

Can I appeal if Anthem denies coverage? Yes. You have the right to internal appeal and, after that is exhausted, external review by an independent review organization under federal law. Deadlines and required documentation are stated on your denial letter.

Is there a generic version of Belsomra? Not as of this review. Confirm current status through the FDA's Orange Book, since generic entry dates can change.

References

1. U.S. Food and Drug Administration. Belsomra (suvorexant) prescribing information, approved August 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204569s000lbl.pdf
2. Kaiser Family Foundation. General research on health insurance appeals and consumer protections. https://www.kff.org/

Note for editorial and medical review: earlier drafts of this page included precise Anthem copay ranges, prior-authorization turnaround times, appeal overturn percentages, savings card terms, and clinical trial effect sizes attributed to PubMed identifiers that could not be verified against the actual cited papers. Those specific numbers have been removed or converted to general, unattributed statements pending verification. Before publication, a reviewer should confirm current Anthem formulary tier and PA policy language directly from Anthem's published documents, confirm current manufacturer savings program terms, and either restore verified trial citations for the clinical evidence section or keep that section general as drafted here.